These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 37284018)

  • 21. Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease.
    Parnetti L; Farotti L; Eusebi P; Chiasserini D; De Carlo C; Giannandrea D; Salvadori N; Lisetti V; Tambasco N; Rossi A; Majbour NK; El-Agnaf O; Calabresi P
    Front Aging Neurosci; 2014; 6():53. PubMed ID: 24744728
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Appropriateness of Applying Cerebrospinal Fluid Biomarker Cutoffs from Alzheimer's Disease to Parkinson's Disease.
    Weinshel S; Irwin DJ; Zhang P; Weintraub D; Shaw LM; Siderowf A; Xie SX
    J Parkinsons Dis; 2022; 12(4):1155-1167. PubMed ID: 35431261
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum NFL levels predict progression of motor impairment and reduction in putamen dopamine transporter binding ratios in de novo Parkinson's disease: An 8-year longitudinal study.
    Ye R; Locascio JJ; Goodheart AE; Quan M; Zhang B; Gomperts SN
    Parkinsonism Relat Disord; 2021 Apr; 85():11-16. PubMed ID: 33639572
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cerebrospinal-fluid Alzheimer's Disease Biomarkers and Blood-Brain Barrier Integrity in a Natural Population of Cognitive Intact Parkinson's Disease Patients.
    Liguori C; Olivola E; Pierantozzi M; Cerroni R; Galati S; Saviozzi V; Mercuri NB; Stefani A
    CNS Neurol Disord Drug Targets; 2017; 16(3):339-345. PubMed ID: 27934563
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson's disease.
    Batzu L; Rota S; Hye A; Heslegrave A; Trivedi D; Gibson LL; Farrell C; Zinzalias P; Rizos A; Zetterberg H; Chaudhuri KR; Aarsland D
    NPJ Parkinsons Dis; 2022 Nov; 8(1):154. PubMed ID: 36371469
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum neurofilament light chain levels reflect cortical neurodegeneration in de novo Parkinson's disease.
    Sampedro F; Pérez-González R; Martínez-Horta S; Marín-Lahoz J; Pagonabarraga J; Kulisevsky J
    Parkinsonism Relat Disord; 2020 May; 74():43-49. PubMed ID: 32334380
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of serum neurofilament light chain and glial fibrillary acidic protein levels with cognitive decline in Parkinson's disease.
    Mao S; Teng X; Li Z; Zu J; Zhang T; Xu C; Cui G
    Brain Res; 2023 Apr; 1805():148271. PubMed ID: 36754139
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
    Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
    JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum Uric Acid Level as a Biomarker in Idiopathic and Genetic (p.A53T Alpha-Synuclein Carriers) Parkinson's Disease: Data from the PPMI Study.
    Koros C; Simitsi AM; Papadimitriou D; Bougea A; Prentakis A; Papagiannakis N; Pachi I; Bozi M; Antonelou R; Angelopoulou E; Beratis I; Papageorgiou SG; Trapali XG; Stamelou M; Stefanis L
    J Parkinsons Dis; 2020; 10(2):481-487. PubMed ID: 32176655
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potential biomarkers relating pathological proteins, neuroinflammatory factors and free radicals in PD patients with cognitive impairment: a cross-sectional study.
    Yu SY; Zuo LJ; Wang F; Chen ZJ; Hu Y; Wang YJ; Wang XM; Zhang W
    BMC Neurol; 2014 May; 14():113. PubMed ID: 24884485
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Brain Amyloid Contribution to Cognitive Dysfunction in Early-Stage Parkinson's Disease: The PPMI Dataset.
    Fiorenzato E; Biundo R; Cecchin D; Frigo AC; Kim J; Weis L; Strafella AP; Antonini A
    J Alzheimers Dis; 2018; 66(1):229-237. PubMed ID: 30282359
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Constipation is Associated with Development of Cognitive Impairment in de novo Parkinson's Disease: A Longitudinal Analysis of Two International Cohorts.
    Leta V; Urso D; Batzu L; Weintraub D; Titova N; Aarsland D; Martinez-Martin P; Borghammer P; van Wamelen DJ; Yousaf T; Rizos A; Rodriguez-Blazquez C; Chung-Faye G; Chaudhuri KR
    J Parkinsons Dis; 2021; 11(3):1209-1219. PubMed ID: 33843697
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma Levels of α-Synuclein, Aβ-40 and T-tau as Biomarkers to Predict Cognitive Impairment in Parkinson's Disease.
    Chen NC; Chen HL; Li SH; Chang YH; Chen MH; Tsai NW; Yu CC; Yang SY; Lu CH; Lin WC
    Front Aging Neurosci; 2020; 12():112. PubMed ID: 32410983
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum Uric Acid in LRRK2 Related Parkinson's Disease: Longitudinal Data from the PPMI Study.
    Bougea A; Koros C; Papagiannakis N; Simitsi AM; Prentakis A; Papadimitriou D; Pachi I; Antonelou R; Angelopoulou E; Beratis I; Bozi M; Papageorgiou SG; Trapali XG; Stamelou M; Stefanis L
    J Parkinsons Dis; 2021; 11(2):633-640. PubMed ID: 33682725
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CSF β-Amyloid 1-42 Predicts Progression to Cognitive Impairment in Newly Diagnosed Parkinson Disease.
    Terrelonge M; Marder KS; Weintraub D; Alcalay RN
    J Mol Neurosci; 2016 Jan; 58(1):88-92. PubMed ID: 26330275
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum Insulin-Like Growth Factor-1 in Parkinson's Disease; Study of Cerebrospinal Fluid Biomarkers and White Matter Microstructure.
    Ghazi Sherbaf F; Mohajer B; Ashraf-Ganjouei A; Mojtahed Zadeh M; Javinani A; Sanjari Moghaddam H; Shirin Shandiz M; Aarabi MH
    Front Endocrinol (Lausanne); 2018; 9():608. PubMed ID: 30450079
    [No Abstract]   [Full Text] [Related]  

  • 37. An increased rate of longitudinal cognitive decline is observed in Parkinson's disease patients with low CSF Aß42 and an APOE ε4 allele.
    Shahid M; Kim J; Leaver K; Hendershott T; Zhu D; Cholerton B; Henderson VW; Tian L; Poston KL
    Neurobiol Dis; 2019 Jul; 127():278-286. PubMed ID: 30826425
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neurofilament light chain as a mediator between LRRK2 mutation and dementia in Parkinson's disease.
    Yang D; Xie H; Wu S; Ying C; Chen Y; Ge Y; Yao R; Li K; Jiang Z; Chen G
    NPJ Parkinsons Dis; 2023 Sep; 9(1):132. PubMed ID: 37699957
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's disease.
    Liu C; Cholerton B; Shi M; Ginghina C; Cain KC; Auinger P; ; Zhang J
    Parkinsonism Relat Disord; 2015 Mar; 21(3):271-6. PubMed ID: 25596881
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlated levels of cerebrospinal fluid pathogenic proteins in drug-naïve Parkinson's disease.
    Murakami H; Tokuda T; El-Agnaf OMA; Ohmichi T; Miki A; Ohashi H; Owan Y; Saito Y; Yano S; Tsukie T; Ikeuchi T; Ono K
    BMC Neurol; 2019 Jun; 19(1):113. PubMed ID: 31164098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.